9/24/2013 9:18:53 AM
Biotie Therapies Corp., a specialized drug development company focused on
neurodegenerative and psychiatric disorders, today announces the outcome of its
planned portfolio review following its success earlier in the year with the
approval and launch of Selincro® in Europe by H. Lundbeck A/S ("Lundbeck") and
the exercise by UCB S.A. ("UCB") of its license for tozadenant (SYN115), for
which Biotie received a USD 20 million milestone.
Help employers find you! Check out all the jobs and post your resume.
comments powered by